title: A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells.
abstract: Bifunctional antibody fusion proteins engaging effector T cells for targeted elimination of tumor cells via CD3 binding have shown efficacy in both preclinical and clinical studies. Different from such a polyclonal T-cell recruitment, an alternative concept is to engage only antigen-specific T-cell subsets. Recruitment of specific subsets of T cells may be as potent but potentially lead to fewer side effects. Tumor-targeted peptide-MHC class I complexes (pMHCI-IgGs) bearing known antigenic peptides complexed with MHC class I molecules mark tumor cells as antigenic and utilize the physiologic way to interact with and activate T-cell receptors. If, for example, virus-specific CD8(+) T cells are addressed, the associated strong antigenicity and tight immune surveillance of the effector cells could lead to efficacious antitumor treatment in various tissues. However, peptide-MHC class I fusions are difficult to express recombinantly, especially when fused to entire antibody molecules. Consequently, current formats are largely limited to small antibody fragment fusions expressed in bacteria followed by refolding or chemical conjugation. Here, we describe a new molecular format bearing a single pMHCI complex per IgG fusion molecule characterized by enhanced stability and expression yields. This molecular format can be expressed in a full immunoglobulin format and can be designed as mono- or bivalent antibody binders. Mol Cancer Ther; 15(9); 2130-42. ©2016 AACR.
authors.affiliation: Large Molecule Research, Roche Innovation Center Munich, Munich, Germany.
authors.forename: Martina
authors.initials: M
authors.lastname: Schmittnaegel
authors.affiliation: Large Molecule Research, Roche Innovation Center Munich, Munich, Germany.
authors.forename: Eike
authors.initials: E
authors.lastname: Hoffmann
authors.affiliation: Large Molecule Research, Roche Innovation Center Munich, Munich, Germany.
authors.forename: Sabine
authors.initials: S
authors.lastname: Imhof-Jung
authors.affiliation: Large Molecule Research, Roche Innovation Center Munich, Munich, Germany.
authors.forename: Cornelia
authors.initials: C
authors.lastname: Fischer
authors.affiliation: Large Molecule Research, Roche Innovation Center Munich, Munich, Germany.
authors.forename: Georg
authors.initials: G
authors.lastname: Drabner
authors.affiliation: Large Molecule Research, Roche Innovation Center Munich, Munich, Germany.
authors.forename: Guy
authors.initials: G
authors.lastname: Georges
authors.affiliation: Discovery Oncology, Roche Pharma Research and Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.
authors.forename: Christian
authors.initials: C
authors.lastname: Klein
authors.affiliation: Therapeutic Modalities, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland. hendrik.knoetgen@roche.com.
authors.forename: Hendrik
authors.initials: H
authors.lastname: Knoetgen
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology*; D018033:Antibodies, Bispecific / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic; D018984:Epitopes, T-Lymphocyte / Q000276:immunology / Q000378:metabolism; D015395:Histocompatibility Antigens Class I / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D010455:Peptides / Q000276:immunology / Q000378:metabolism; D010750:Phosphoproteins / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D011485:Protein Binding; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism; D014763:Viral Matrix Proteins / Q000737:chemistry / Q000276:immunology / Q000378:metabolism
chemical_list: D000906:Antibodies; D018033:Antibodies, Bispecific; D018984:Epitopes, T-Lymphocyte; D015395:Histocompatibility Antigens Class I; D007074:Immunoglobulin G; D010455:Peptides; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa